SNSE

Sensei Biotherapeutics Inc

SNSE, USA

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

https://www.senseibio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SNSE
stock
SNSE

Does Empresa Nacional de Telecomunicaciones (SNSE:ENTEL) Have A Healthy Balance Sheet? simplywall.st

Read more →
SNSE
stock
SNSE

Is Enel Chile (SNSE:ENELCHILE) A Risky Investment? simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$32.5

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.47

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-19.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-16.56 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

73.92 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 7.20% of the total shares of Sensei Biotherapeutics Inc

1.

Vanguard Group Inc

(2.3064%)

since

2025/06/30

2.

Ikarian Capital, LLC

(1.7837%)

since

2025/06/30

3.

Catalio Capital Management, LP

(1.1669%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(0.4481%)

since

2025/07/31

5.

Fidelity Extended Market Index

(0.3649%)

since

2025/07/31

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2713%)

since

2025/07/31

7.

UBS Group AG

(0.1697%)

since

2025/06/30

8.

Fidelity Series Total Market Index

(0.126%)

since

2025/07/31

9.

Fidelity Total Market Index

(0.1123%)

since

2025/07/31

10.

NT Ext Equity Mkt Idx Fd - L

(0.071%)

since

2025/06/30

11.

Northern Trust Extended Eq Market Idx

(0.071%)

since

2025/06/30

12.

Nwf Advisory Services Inc

(0.0655%)

since

2025/03/31

13.

Bank of America Corp

(0.0462%)

since

2025/06/30

14.

Quint:Essence Strat Social Media&Tech P

(0.0396%)

since

2025/07/31

15.

NT Ext Equity Mkt Idx Fd - NL

(0.028%)

since

2025/06/30

16.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0217%)

since

2025/06/30

17.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0201%)

since

2025/06/30

18.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0169%)

since

2024/12/31

19.

Spartan Total Market Index Pool G

(0.0145%)

since

2025/07/31

20.

State St US Extended Mkt Indx NL Cl C

(0.0123%)

since

2025/08/31

21.

SBI Securities Co Ltd

(0.0118%)

since

2025/06/30

22.

Fidelity Nasdaq Composite Index

(0.0098%)

since

2025/07/31

23.

SSgA U.S. Total Market Index Strategy

(0.0051%)

since

2025/03/31

24.

State St US Ttl Mkt Indx NL Cl A

(0.0044%)

since

2025/08/31

25.

Northern Trust Wilshire 5000

(0.0039%)

since

2025/06/30

26.

JPMorgan Chase & Co

(0.0025%)

since

2025/06/30

27.

Spartan Extended Market Index Pool F

(0.0025%)

since

2025/07/31

28.

Morgan Stanley - Brokerage Accounts

(0.0008%)

since

2025/06/30

29.

BNP Paribas Arbitrage, SA

(0.0007%)

since

2025/06/30

30.

Guggenheim Active Allocation Fund

(0.0005%)

since

2025/05/31

31.

Deuterium Capital Management, LLC

(0%)

since

2025/03/31

32.

State Street Corp

(0%)

since

2025/06/30

34.

Tower Research Capital LLC

(0%)

since

2025/06/30

35.

Northern Trust Corp

(0%)

since

2025/06/30

36.

Bridgeway Capital Management, LLC

(0%)

since

2025/03/31

37.

Barclays PLC

(0%)

since

2025/06/30

38.

Citadel Advisors Llc

(0%)

since

2025/03/31

39.

XTX Topco Ltd

(0%)

since

2025/03/31

40.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-3.62

EPS Estimate

-4.11

EPS Difference

0.49

Surprise Percent

11.9221%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(4.5)
Net Net
Strong Net-Net(8)
Quality
Moderate Quality(6)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.